ECE2017 Eposter Presentations: Adrenal and Neuroendocrine Tumours Endocrine tumours and neoplasia (50 abstracts)
Glucose metabolism abnormalities and insulin resistance are frequent in well diferentiated digestive NETs
Ana P Santos 1, , Ana C Santos 2, , Clara Castro 1, , Luís Raposo 2 , Isabel Torres 1 , Rui Henrique 6, , Mariana P Monteiro 3 & M Helena Cardoso 3,
1IPO Porto, Porto, Portugal; 2ISPUP/EPI Unit - UP, Porto, Portugal; 3UMIB/ICBAS - UP, Porto, Portugal; 4CHP, Porto, Portugal; 5FMUP - UP, Porto, Portugal; 6IPO Porto, Research Unit, Porto, Portugal; 7EPOP, Porto, Portugal.
Introduction: Incidence of Digestive NETs (DNETs) has increased in the last 40 years. Visceral obesity, metabolic syndrome (MetS) and insulin resistance (IR) have been associated with several types of cancer.
Aim: To evaluate possible associations of obesity, hyperinsulinemia and IR with well-differentiated (WD) DNETs through a case control study.
Materials and methods: Ninety-six patients with gastrointestinal (75.0%) and pNET (22.9%) WD DNETs were recruited from Endocrine Tumours Clinic of IPO Porto and cross-matched with a control group (n=96) from PORMETS, a nationwide epidemiological study designed to evaluate the MetS prevalence in the general population, pair-matched by age, gender and place of birth. Hyperinsulinemia and IR were defined according to Mattews’s classification. WD DNETs were classified according to primary tumour localization, hormonal secretion, TNM stage and WHO grading.
Results: MetS was present in 45.8% of WD DNETs. According to grading, 66.7% were G1 and 27.1% were G2 tumours. The disease was localized in 31.3%, locoregional in 16.7% and disseminated in 43.8%. Both patients and controls had high mean body weight (26.9 vs 27.2 kg/m2, P=0.645). No significant differences were found between the two groups for waist circumference, Fasting Plasma Insulin (FPI) and HOMA-IR (P=0.236; P=0.372 and P=0.274, respectively). Median Fasting Plasma Glucose (FPG) and Impaired Fasting Glucose (IFG) frequency were higher in WD DNETs (P<0.001 and P=0.013, respectively). FPG≥100 mg/dl and HOMA-RI≥5 were associated with a higher risk for WD DNETs (OR 4.3 (95%CI 2.3–8.2, P<0.001); OR 4.1 (95%CI 1.2–13.5, P=0.014), respectively). When anthropometric and metabolic parameters are compared, there was no difference between somatostatin analogues users and no-users.
Conclusion: Association of glucose metabolism abnormalities and IR with WD DNETs confirmation can open new perspectives for prevention and treatment, through modifying lifestyle and insulin sensitizers use.
Volume 49
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more